Top

Published in:

01-08-2018 | Letter to the Editor

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200

Authors: Kaito Harada, Noriko Doki, Yasushi Miyazaki, Atsushi Wakita, Shigeki Ohtake, Satoru Takada, Hirokazu Komatsu, Kohmei Kubo, Akihiro Takeshita, Yoko Adachi, Hitoshi Kiyoi, Takuhiro Yamaguchi, Minoru Yoshida, Tomoki Naoe, Kazuteru Ohashi

Published in: Annals of Hematology | Issue 8/2018

Excerpt

Dear Editor, …

Available only for authorised users

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K (2018) Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. Ann Hematol 97:73–81CrossRefPubMed

Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA (2005) Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293:203–211CrossRefPubMed

Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Neuberg DS, Fathi AT (2013) Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 88:642–646CrossRefPubMedPubMedCentral

Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R (2012) Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. Int J Hematol 96:84–93CrossRefPubMed

Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A, Hoglund M (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179–4187CrossRefPubMed

Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH (2006) Age and acute myeloid leukemia. Blood 107:3481–3485CrossRefPubMedPubMedCentral

Ossenkoppele G, Löwenberg B (2015) How I treat the older patient with acute myeloid leukemia. Blood 125:767–774CrossRefPubMed

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. Version 3. 2017. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp). Accessed 2017 Dec 25

Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106:1090–1098CrossRefPubMed

Title: Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200
Authors: Kaito Harada
Noriko Doki
Yasushi Miyazaki
Atsushi Wakita
Shigeki Ohtake
Satoru Takada
Hirokazu Komatsu
Kohmei Kubo
Akihiro Takeshita
Yoko Adachi
Hitoshi Kiyoi
Takuhiro Yamaguchi
Minoru Yoshida
Tomoki Naoe
Kazuteru Ohashi
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 8/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3281-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2018

Comorbidities, repeated hospitalizations, and age ≥ 80 years as indicators of anemia development in the older population

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis

Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study

Major response of PNH to an AML chemotherapy protocol

Necrobiotic xanthogranuloma: a 30-year single-center experience

Late-onset hemophagocytic lymphohistiocytosis with varicella zoster virus and Epstein-Barr virus co-infection after umbilical cord blood transplantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page